Authors

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Holly Pederson, MD, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.

Segment III explores how clinicians approach second-line therapy in follicular lymphoma, particularly as new options challenge traditional standards. Dr. Mehta reviews how CD20-directed therapies have historically anchored relapse treatment but notes the shift toward more diverse targets, including CD3 (via bispecific antibodies) and CD19 (via tafasitamab and other emerging agents). This expansion raises important clinical questions around target sequencing, resistance, and whether using a target early may “burn” it for future lines of therapy. The discussion highlights the role of bispecific antibodies, CAR T-cell therapy, and CD19-based agents, along with practical considerations such as infusion requirements, monitoring demands, and access to treatment centers with specialized capabilities. Dr. Mehta explains how academic-community partnerships influence real-world treatment pathways, especially for therapies with more complex toxicity profiles like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). NP Bailey contributes perspective on patient logistics, including distance to treatment centers, social support needs, and how the complexity of treatment may shape patient decision-making. She emphasizes the importance of aligning therapy selection with patient lifestyle and functional status, a theme that recurs throughout the program. This segment underscores the increasingly individualized nature of second-line therapy, where clinicians must integrate disease biology, treatment history, patient comorbidities, and practical feasibility. As the faculty outline, modern management requires balancing efficacy with safety, accessibility, and long-term planning, ensuring that patients receive not only effective but sustainable care.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Xichun Hu, MD, PhD, discusses a study of tibremciclib plus fulvestrant in HR+/HER2– advanced breast cancer following progression on endocrine therapy.

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.